

Table S1. Clinical outcomes of patients with B-cell malignancy developing COVID-19

	Study design	Country (centres)	Number of patients, N	Male sex, N (%)	Median age (IQR)	Moderate to severe COVID-19, N (%)	ICU admission, N (%)	Overall mortality, N (%)
Multiple myeloma								
	Martinez-Lopez <i>J et al.</i>	Spain (73 centres)	167	95 (57)	71 (62-78)	128 (77)	NA	56 (34)
	Chari <i>et al.</i>	International (10 countries)	617	347 (56)	69 (34-92)	512 (83)	NA	212 (34)
Chronic lymphocytic leukemia								
	Scarfò <i>et al.</i>	International (22 countries)	190	126 (66)	72 (48-94)	169 (89)	39 (21)	55 (32)
	Mato <i>et al.</i>	International (43 centres)	198	125 (63)	70.5 (38-98)	178 (90)	68 (35)	66 (33)
	Blixt <i>et al.</i>	Sweden (3 centres)	60	39 (65)	71 (43-97)	46 (77)	11 (18)	14 (23)
Lymphoma								
	Regalado-Artamendi <i>et al.</i>	Spain (19 centres)	177	99 (56)	70 (56-77)	151 (85)	16 (9)	61 (34)
	Duléry <i>et al.</i>	France (16 centres)	111	70 (63)	65 (19-92)	111 (100)	NA	34 (31)
CAR-T cell therapy recipients for the treatment of relapsed/refractory B-cell malignancy								
	Busca <i>et al.</i>	European (18 centres)	30	17 (57)	57 (51-64)	21 (70)	13 (43)	15 (50)
	Spanjaart <i>et al.</i>	European (11 countries)	56	32 (57)	57.7 (5.2–72.8)	45 (80%)	22 (39)	25 (45)

ICU= intensive care unit, IQR= interquartile range, NA= not available

Table S2. Vaccine responses to SARS-CoV-2 in patients with B-cell malignancy

	Study design	Country (centres)	Number of patients, N	Male sex, N (%)	Median age (IQR)	Type of vaccine (%)	Number of vaccine doses (%)	Antibody response, N (%)	T-cell response, N (%)
Multiple myeloma									
	Nooka <i>et al.</i>	USA (Atlanta)	238	124 (52)	67 (38-90)	BNT162b2 (62) mRNA-1273 (36) Ad26.COVS.2 (2)	Second (100)	208 (87)	NA
	Ramasamy <i>et al.</i>	UK (30 centres)	218	120 (56)	NA	BNT162b2 (31) ChAdOx1 nCoV-19 (44) Unknown (25)	Second (100)	198 (93)	102/167 (62)
	Avivi <i>et al.</i>	Israel (Tel Aviv)	171	97 (57)	70 (38-94)	BNT162b2 (100)	Second (100)	133 (78)	NA
Chronic lymphocytic leukemia									
	Molica <i>et al.</i>	-	2082	NA	NA	NA	Second (100)	1083 (52)	NA
	Lyski <i>et al.</i>	USA (Portland)	16	10 (63)	64.5 (62-68)	BNT162b2 (69) mRNA-1273 (19) Unknown (12)	Second (100)	4 (25)	10 (63)
Lymphoma									
	Perry <i>et al.</i>	Israel (Tel Aviv)	149	88 (59)	64 (20-92)	BNT162b2 (100)	Second (100)	73 (49)	NA
	Riise <i>et al.</i>	Norway	118	59 (50)	71 (22-89)	BNT162b2 (87) mRNA-1273 (12) ChAdOx1 nCoV-19 (1)	Second (100)	7/110 (6)	20/29 (68)
CAR-T cell therapy recipients for the treatment of relapsed/refractory B-cell malignancy									
	Sesques <i>et al.</i>	France (Lyon)	33	17 (52)	65 (52-72)	BNT162b2 (79) mRNA-1273 (21)	Third (33) Fourth (67)	6 (18)	14 (42)
	Gastinne <i>et al.</i>	France (Nantes)	23	14 (61)	62 (21-79)	BNT162b2 (100)	First (100)	4 (17) *	NA
	Dahiya <i>et al.</i>	USA (Baltimore)	18	NA	50.5 (24-87)	BNT162b2 (44) mRNA-1273 (56)	First (22) Second (78)	1 (6)	NA

NA= not available

* After second dose of BNT162b2: 6 of 20 (30%) seroconverted